Works matching IS 03407004 AND DT 2023 AND VI 72 AND IP 4

Results: 22

Correction to: Anti‑PD‑1 antibody‑activated Th17 cells subvert re‑invigoration of antitumor cytotoxic T‑lymphocytes via myeloid cell‑derived COX‑2/PGE2.

Published in:

2023

By:

Li, Qingsheng;
Goggin, Kevin E.;
Seo, SeonYeong;
Warawa, Jonathan M.;
Egilmez, Nejat K.

Publication type:

Correction Notice

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

Published in:

2023

By:

Weber, Jeffrey S.;
Poretta, Tayla;
Stwalley, Brian D.;
Sakkal, Leon A.;
Du, Ella X.;
Wang, Travis;
Chen, Yan;
Wang, Yan;
Betts, Keith A.;
Shoushtari, Alexander N.

Publication type:

Correction Notice

PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 1003, doi. 10.1007/s00262-022-03309-y

By:

Mocan, Lavinia Patricia;
Craciun, Rares;
Grapa, Cristiana;
Melincovici, Carmen Stanca;
Rusu, Ioana;
Al Hajjar, Nadim;
Sparchez, Zeno;
Leucuta, Daniel;
Ilies, Maria;
Sparchez, Mihaela;
Mocan, Tudor;
Mihu, Carmen Mihaela

Publication type:

Article

Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 1015, doi. 10.1007/s00262-022-03308-z

By:

Ping, Yu;
Shan, Jiqi;
Liu, Yaqing;
Liu, Fengsen;
Wang, Liuya;
Liu, Zhangnan;
Li, Jieyao;
Yue, Dongli;
Wang, Liping;
Chen, Xinfeng;
Zhang, Yi

Publication type:

Article

Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 985, doi. 10.1007/s00262-022-03307-0

By:

Shi, Ranran;
Zhou, Xiuman;
Pang, Liwei;
Wang, Mingshuang;
Li, Yubing;
Chen, Chunxia;
Ning, Haoming;
Zhang, Lihan;
Yue, Guangxing;
Qiu, Lu;
Zhao, Wenshan;
Qi, Yuanming;
Wu, Yahong;
Gao, Yanfeng

Publication type:

Article

αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 969, doi. 10.1007/s00262-022-03306-1

By:

Pan, Mingzhu;
Wang, Fei;
Nan, Lidi;
Yang, Siyu;
Qi, Jinyao;
Xie, Jiajun;
Shao, Shuai;
zou, Hongyi;
Wang, Min;
Sun, Fumou;
Zhang, Juan

Publication type:

Article

Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 957, doi. 10.1007/s00262-022-03303-4

By:

Suematsu, Masaya;
Yagyu, Shigeki;
Yoshida, Hideki;
Osone, Shinya;
Nakazawa, Yozo;
Sugita, Kanji;
Imamura, Toshihiko;
Iehara, Tomoko

Publication type:

Article

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 945, doi. 10.1007/s00262-022-03302-5

By:

Weber, Jeffrey S.;
Poretta, Tayla;
Stwalley, Brian D.;
Sakkal, Leon A.;
Du, Ella X.;
Wang, Travis;
Chen, Yan;
Wang, Yan;
Betts, Keith A.;
Shoushtari, Alexander N.

Publication type:

Article

Live attenuated VZV vaccination induces antitumor immunity in ATLL patients.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 929, doi. 10.1007/s00262-022-03301-6

By:

Jo, Tatsuro;
Kubota-Koketsu, Ritsuko;
Kaneko, Yohei;
Sakai, Takahiro;
Noguchi, Kazuhiro;
Irie, Sadaharu;
Matsuo, Masatoshi;
Taguchi, Jun;
Abe, Kuniko;
Shigematsu, Kazuto

Publication type:

Article

ZIM3 activation of CCL25 expression in pulmonary metastatic nodules of osteosarcoma recruits M2 macrophages to promote metastatic growth.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 903, doi. 10.1007/s00262-022-03300-7

By:

Li, Jing;
Zhao, Chenguang;
Wang, Dong;
Wang, Shuang;
Dong, Hui;
Wang, Difan;
Yang, Yubing;
Li, Jiaxi;
Cui, Feng;
He, Xijing;
Qin, Jie

Publication type:

Article

Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 797, doi. 10.1007/s00262-022-03299-x

By:

Beelen, Nicky A.;
Ehlers, Femke A. I.;
Bos, Gerard M. J.;
Wieten, Lotte

Publication type:

Article

Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 1029, doi. 10.1007/s00262-022-03298-y

By:

Guo, Wei;
Huai, Qilin;
Zhou, Bolun;
Guo, Lei;
Sun, Li;
Xue, Xuemin;
Tan, Fengwei;
Xue, Qi;
Gao, Shugeng;
He, Jie

Publication type:

Article

Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 895, doi. 10.1007/s00262-022-03295-1

By:

Ashkar, Motaz;
Chandra, Shruti;
Vege, Santhi Swaroop;
Takahashi, Hiroaki;
Takahashi, Naoki;
McWilliams, Robert R.

Publication type:

Article

Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 851, doi. 10.1007/s00262-022-03293-3

By:

Kajihara, Nabeel;
Kobayashi, Takuto;
Otsuka, Ryo;
Nio-Kobayashi, Junko;
Oshino, Tomohiro;
Takahashi, Masato;
Imanishi, Seiichi;
Hashimoto, Ari;
Wada, Haruka;
Seino, Ken-ichiro

Publication type:

Article

Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 865, doi. 10.1007/s00262-022-03292-4

By:

Okita, Riki;
Mimura-Kimura, Yuka;
Kawamoto, Nobutaka;
Yamamoto, Naoki;
Umeda, Masashi;
Okada, Masanori;
Inokawa, Hidetoshi;
Mimura, Yusuke;
Murakami, Tomoyuki;
Nakata, Masao;
Okabe, Kazunori

Publication type:

Article

Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 841, doi. 10.1007/s00262-022-03291-5

By:

Fukuokaya, Wataru;
Yanagisawa, Takafumi;
Hashimoto, Masaki;
Yamamoto, Shutaro;
Koike, Yuhei;
Imai, Yu;
Iwatani, Kosuke;
Onuma, Hajime;
Ito, Kagenori;
Urabe, Fumihiko;
Tsuzuki, Shunsuke;
Kimura, Shoji;
Miki, Jun;
Oyama, Yu;
Abe, Hirokazu;
Kimura, Takahiro

Publication type:

Article

Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 917, doi. 10.1007/s00262-022-03290-6

By:

Li, Ke;
Xu, Jing;
Wang, Jing;
Lu, Chong;
Dai, Yilin;
Dai, Qing;
Zhang, Wang;
Xu, Congjian;
Wu, Shu;
Kang, Yu

Publication type:

Article

PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 881, doi. 10.1007/s00262-022-03288-0

By:

Liu, Jianhua;
Chen, Hao;
Qiao, Guibin;
Zhang, Jia-Tao;
Zhang, Shuaitong;
Zhu, Changbin;
Chen, Yu;
Tang, Jiming;
Li, Weiwei;
Wang, Siyun;
Tian, Hongxia;
Chen, Zhihong;
Ma, Dong;
Tian, Jie;
Wu, Yi-Long

Publication type:

Article

Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 805, doi. 10.1007/s00262-022-03287-1

By:

Owen, Kathryn;
Ghaly, Ramy;
Shohdy, Kyrillus S.;
Thistlethwaite, Fiona

Publication type:

Article

Induction of the activating transcription factor-4 in the intratumoral CD8+ T cells sustains their viability and anti-tumor activities.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 815, doi. 10.1007/s00262-022-03286-2

By:

Lu, Zhen;
Bae, Eun-Ah;
Verginadis, Ioannis I.;
Zhang, Hongru;
Cho, Christina;
McBrearty, Noreen;
George, Subin S.;
Diehl, J. Alan;
Koumenis, Constantinos;
Bradley, Linda M.;
Fuchs, Serge Y.

Publication type:

Article

Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE2.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 1047, doi. 10.1007/s00262-022-03285-3

By:

Li, Qingsheng;
Goggin, Kevin E.;
Seo, SeonYeong;
Warawa, Jonathan M.;
Egilmez, Nejat K.

Publication type:

Article

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 4, p. 827, doi. 10.1007/s00262-022-03283-5

By:

Español-Rego, Marta;
Fernández-Martos, Carlos;
Elez, Elena;
Foguet, Carles;
Pedrosa, Leire;
Rodríguez, Nuria;
Ruiz-Casado, Ana;
Pineda, Estela;
Cid, Joan;
Cabezón, Raquel;
Oliveres, Helena;
Lozano, Miquel;
Ginés, Angels;
García-Criado, Angeles;
Ayuso, Juan Ramon;
Pagés, Mario;
Cuatrecasas, Miriam;
Torres, Ferràn;
Thomson, Timothy;
Cascante, Marta

Publication type:

Article

Works matching IS 03407004 AND DT 2023 AND VI 72 AND IP 4

Correction to: Anti‑PD‑1 antibody‑activated Th17 cells subvert re‑invigoration of antitumor cytotoxic T‑lymphocytes via myeloid cell‑derived COX‑2/PGE<sub>2</sub>.

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma.

Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8<sup>+</sup> T cell function.

Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer.

αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.

Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

Live attenuated VZV vaccination induces antitumor immunity in ATLL patients.

ZIM3 activation of CCL25 expression in pulmonary metastatic nodules of osteosarcoma recruits M2 macrophages to promote metastatic growth.

Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy.

Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer.

Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification.

Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.

Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.

Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.

Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.

PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.

Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.

Induction of the activating transcription factor-4 in the intratumoral CD8+ T cells sustains their viability and anti-tumor activities.

Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE<sub>2</sub>.

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.